Literature DB >> 18355689

Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans.

Jo Ann V Antenor-Dorsey1, Joanne Markham, Stephen M Moerlein, Tom O Videen, Joel S Perlmutter.   

Abstract

Positron emission tomography measurements of dopaminergic D2-like receptors may provide important insights into disorders such as Parkinson's disease, schizophrenia, dystonia and Tourette's syndrome. The positron emission tomography (PET) radioligand [18F](N-methyl)benperidol ([18F]NMB) has high affinity and selectivity for D2-like receptors and is not displaced by endogenous dopamine. The goal of this study is to evaluate the use of a graphical method utilizing a reference tissue region for [18F]-NMB PET analysis by comparisons to an explicit three-compartment tracer kinetic model and graphical method that use arterial blood measurements. We estimated binding potential (BP) in the caudate and putamen using all three methods in 16 humans and found that the three-compartment tracer kinetic method provided the highest BP estimates while the graphical method using a reference region yielded the lowest estimates (P<.0001 by repeated-measures ANOVA). However, the three methods yielded highly correlated BP estimates for the two regions of interest. We conclude that the graphical method using a reference region still provides a useful estimate of BP comparable to methods using arterial blood sampling, especially since the reference region method is less invasive and computationally more straightforward, thereby simplifying these measurements.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18355689      PMCID: PMC2390782          DOI: 10.1016/j.nucmedbio.2007.12.004

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  49 in total

1.  Alterations in dopaminergic receptors in Huntington's disease.

Authors:  T D Reisine; J Z Fields; L Z Stern; P C Johnson; E D Bird; H I Yamamura
Journal:  Life Sci       Date:  1977-10-15       Impact factor: 5.037

2.  Radiation dosimetry of [18F] (N-methyl)benperidol as determined by whole-body PET imaging of primates.

Authors:  S M Moerlein; J S Perlmutter; P D Cutler; M J Welch
Journal:  Nucl Med Biol       Date:  1997-05       Impact factor: 2.408

3.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease.

Authors:  T Lee; P Seeman; A Rajput; I J Farley; O Hornykiewicz
Journal:  Nature       Date:  1978-05-04       Impact factor: 49.962

4.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

5.  Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans.

Authors:  Patrizia Riccardi; Rui Li; Mohammad Sib Ansari; David Zald; Sohee Park; Benoit Dawant; Sharlet Anderson; Mikisha Doop; Neil Woodward; Evan Schoenberg; Dennis Schmidt; Ronald Baldwin; Robert Kessler
Journal:  Neuropsychopharmacology       Date:  2006-05       Impact factor: 7.853

Review 6.  Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.

Authors:  P G Strange
Journal:  Mov Disord       Date:  1993-07       Impact factor: 10.338

7.  Improved delineation of human dopamine receptors using [18F]-N-methylspiroperidol and PET.

Authors:  C D Arnett; A P Wolf; C Y Shiue; J S Fowler; R R MacGregor; D R Christman; M R Smith
Journal:  J Nucl Med       Date:  1986-12       Impact factor: 10.057

8.  Cerebral blood volume measured with inhaled C15O and positron emission tomography.

Authors:  W R Martin; W J Powers; M E Raichle
Journal:  J Cereb Blood Flow Metab       Date:  1987-08       Impact factor: 6.200

9.  Specific, reversible binding of [18F]benperidol to baboon D2 receptors: PET evaluation of an improved 18F-labeled ligand.

Authors:  S M Moerlein; J S Perlmutter; M J Welch
Journal:  Nucl Med Biol       Date:  1995-08       Impact factor: 2.408

10.  Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging.

Authors:  M Ghaemi; R Hilker; J Rudolf; J Sobesky; W-D Heiss
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-11       Impact factor: 10.154

View more
  8 in total

1.  Characterization of extrastriatal D2 in vivo specific binding of [¹⁸F](N-methyl)benperidol using PET.

Authors:  Sarah A Eisenstein; Jon M Koller; Marilyn Piccirillo; Ana Kim; Jo Ann V Antenor-Dorsey; Tom O Videen; Abraham Z Snyder; Morvarid Karimi; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey
Journal:  Synapse       Date:  2012-05-15       Impact factor: 2.562

2.  A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[(11)C]methyl)benperidol.

Authors:  Sarah A Eisenstein; Jo Ann V Antenor-Dorsey; Danuta M Gredysa; Jonathan M Koller; Emily C Bihun; Samantha A Ranck; Ana Maria Arbeláez; Samuel Klein; Joel S Perlmutter; Stephen M Moerlein; Kevin J Black; Tamara Hershey
Journal:  Synapse       Date:  2013-05-30       Impact factor: 2.562

3.  Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status.

Authors:  Sarah A Eisenstein; Ryan Bogdan; Latisha Love-Gregory; Nadia S Corral-Frías; Jonathan M Koller; Kevin J Black; Stephen M Moerlein; Joel S Perlmutter; Deanna M Barch; Tamara Hershey
Journal:  Synapse       Date:  2016-06-17       Impact factor: 2.562

4.  Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia.

Authors:  Sarah A Eisenstein; Ryan Bogdan; Ling Chen; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey; Deanna M Barch
Journal:  J Psychiatr Res       Date:  2016-11-17       Impact factor: 4.791

5.  Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect?

Authors:  Morvarid Karimi; Stephen M Moerlein; Tom O Videen; Robert R Luedtke; Michelle Taylor; Robert H Mach; Joel S Perlmutter
Journal:  Mov Disord       Date:  2010-10-19       Impact factor: 10.338

6.  Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity.

Authors:  Sarah A Eisenstein; Danuta M Gredysa; Jo Ann Antenor-Dorsey; Leonard Green; Ana Maria Arbeláez; Jonathan M Koller; Kevin J Black; Joel S Perlmutter; Stephen M Moerlein; Tamara Hershey
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

7.  Revisiting the Logan plot to account for non-negligible blood volume in brain tissue.

Authors:  Martin Schain; Patrik Fazio; Ladislav Mrzljak; Nahid Amini; Nabil Al-Tawil; Cheryl Fitzer-Attas; Juliana Bronzova; Bernhard Landwehrmeyer; Christina Sampaio; Christer Halldin; Andrea Varrone
Journal:  EJNMMI Res       Date:  2017-08-18       Impact factor: 3.138

8.  Impact of an Adenosine A2A Receptor Agonist and Antagonist on Binding of the Dopamine D2 Receptor Ligand [11C]raclopride in the Rodent Striatum.

Authors:  Kavya Prasad; Erik F J de Vries; Jürgen W A Sijbesma; Lara Garcia-Varela; Daniel A Vazquez-Matias; Rodrigo Moraga-Amaro; Antoon T M Willemsen; Rudi A J O Dierckx; Aren van Waarde
Journal:  Mol Pharm       Date:  2022-07-18       Impact factor: 5.364

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.